Mark Boguski has become vice president and global head of genomics technologies and informatics at the Novartis Institutes for BioMedical Research in Cambridge, Mass., he told Genome Technology a GenomeWeb News sister publication.
Martha Trela has joined Affymetrix in a sales and marketing position, GenomeWeb News has learned. She comes to Affymetrix from Applied Biosystems, where she was vice president for worldwide marketing programs and communications.
Timothy Mayleben has joined the board of directors of Rubicon Genomics, replacing Richard Sloan, the Ann Arbor, Mich.-based company said today. Most recently, he was COO and CFO of Esperion Therapeutics, which was recently acquired by Pfizer.
Maclyn McCarty, who co-discovered that genes consist of DNA, died on Jan. 2, Rockefeller University said last week. He was 93. Together with Oswald Avery and Colin MacLeod, he showed in the 1940's that DNA, not proteins, carry genetic information. He held an undergraduate degree in biochemistry from Stanford University and a medical degree from Johns Hopkins University. McCarty, who worked at Rockefeller University for more than 60 years, received a Special Achievement in Medical Science award from the Lasker Foundation in 1994.
Svante Pääbo has won the Louis-Jeantet-Prize for Medicine for his research on the evolution of the human genome in comparison to that of other primates. He is an honorary professor of genetics and evolutionary biology and a director of the Max-Planck-Institute for Evolutionary Anthropology in
Michael Cosgrove, formerly director of enterprise systems at image informatics firm Scimagix, has left the company, according to last week's BioInform, a GenomeWeb News publication. Scimagix was acquired by image analysis software firm BioImagene in November. Cosgrove said he is "currently exploring other opportunities within the bioinformatics arena."
Oscient Pharmaceuticals has elected John Voris to its board of directors. Voris comes to Oscient from Eli Lilly, where he was executive vice president of Lilly subsidiary PCS Health Systems. He holds a BA and an MBA from the Kelley School of Business at Indiana University. Oscient's board also announced the resignation of William Rutter.
Stephen Costalas has been named executive vice president, general counsel, and secretary at Pharmacopeia Drug Discovery, the
Terence McGowan has been appointed director of institutional advancement at the Boston Biomedical Research Institute, based in
Robert Saltmarsh has been promoted to chief financial officer of Nanogen, the San Diego-based company said last week. He joined Nanogen as vice president of corporate development in September. Most recently, he was a consultant for several startup companies and taught entrepreneurial finance at the University of California at Riverside. Saltmarsh holds a BA in economics and an MBA in finance from the University of Michigan.
Trevor Nicholls has become a member of the European business development team of Affymetrix, the company said in an SEC filing last week. He used to be Affymetrix's executive vice president for product marketing and development.
Ton Bunt has been named senior vice president for clinical development and medical affairs of Oscient Pharmaceuticals, the Waltham, Mass.-based company said last week. He used to be senior medical director of the hypertension group of Merck. Bunt holds an MD and a PhD from the University of Leiden in the
Charles Craig has become president of the Georgia Biomedical Partnership, the industry organization said last week. He is the first full-time president of GBP. Previously, Craig was director of publications for the Biotechnology Industry Organization. He holds a Master's degree in journalism from Louisiana State University and a BA from the University of Virginia.
Jeffrey Allard has become vice president and chief scientific officer of Fujirebio Diagnostics, the Mavern, Pa.-based company said last week. He comes to FDI from Immunicon, where he was vice president of clinical research and development. Allard holds a PhD in biochemistry from Dartmouth College,an MS in immunology from Idaho State University, and a BS in pre-veterinary medicine from the University of New Hampshire.
Burrill has made a number of promotions and staff changes, the San Francisco-based merchant bank said last week. Giovanni Ferrara, Richard Haiduck, and James Watson were promoted to managing directors; Bryant Fong has become principal; Stephen Kujawa has become director; and David Haselwood and Rizwan Velji have become senior associates. In addition, the company appointed Ann Hanham, John Kim, Roger Wyse, Mike Ullman, John Haag, and Tim Young as general partners of the Burrill Life Sciences Capital Fund III.